These data suggest that development of novel pharmacological modulators that can modulate HMGB1 and its receptors (RAGE and TLR4) and control or reduce neuroinflammation may present additional therapeutic strategies to current AD treatment. The gene discussed is TLR4; the disease is Alzheimer disease.